Physician profile
Bryan D Riggeal
NPI 1104023308
$20,131.35
in general payments reported to CMS, 2019-2025
64 companies · $3,460 in 2025
The $3,460 reported for 2025 was more than what 87% of Neuro-Ophthalmology providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,174 · 2020: $1,588 · 2021: $2,957 · 2022: $2,976 · 2023: $3,426 · 2024: $3,551 · 2025: $3,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $236 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,051.35 |
| Education | $235.51 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,242.55 | 2021-2025 | Ubrelvy, Qulipta |
| Teva Pharmaceuticals USA, INC. | $2,049.82 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Amgen INC. | $1,562.90 | 2019-2025 | Aimovig, Uplizna, Tepezza |
| Ucb, INC. | $1,545.55 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Argenx US, INC. | $1,493.25 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Sk Life Science, INC. | $1,378.53 | 2020-2025 | Xcopri |
| Alexion Pharmaceuticals, INC. | $1,097.16 | 2020-2025 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $789.81 | 2019-2025 | |
| Horizon Therapeutics Plc | $646.91 | 2019-2023 | Uplizna, Tepezza |
| Eisai INC. | $576.07 | 2019-2025 | |
| Greenwich Biosciences, INC. | $566.64 | 2019-2021 | |
| Pfizer INC. | $558.87 | 2021-2025 | |
| Genzyme Corporation | $511.94 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $486.36 | 2022-2024 | |
| Allergan, INC. | $477.56 | 2019-2021 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Riggeal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.